Letrozol Heumann 2,5 mg

Description

Contraindications

• hypersensitivity to the active substance or to any of the excipients
• hormonal status characteristic of the premenopausal period (if there are no indicators of full menopause)
• lactulose intolerance, glucose-galactose malabsorption syndrome
• pregnancy, lactation period
• Children and adolescents under 18 years of age

Drug interactions

• No clinically significant interactions were found when the drug was administered concomitantly with cimetidine and warfarin.
• Clinical experience regarding the use of the drug in combination with other antineoplastic drugs is currently not available.
• According to the studies, letrozole inhibits the activity of the cytochrome P450 isoenzymes CYP2A6 and CYP2C19 (the latter moderately). The CYP2A6 isoenzyme does not play a significant role in the metabolism of the drug. In experiments, letrozole at concentrations 100 times higher than plasma equilibrium values has no ability to significantly inhibit the metabolism of diazepam (a substrate for CYP2C19). Therefore, clinically relevant interactions with the CYP2C19 isoenzyme are unlikely. Nevertheless, caution should be exercised when co-administering letrozole with drugs that are mainly metabolised by the above isoenzymes and have a narrow therapeutic index.
• There are no data on other clinically relevant interactions with other medicinal products (benzodiazepines, barbiturates, diclofenac sodium, ibuprofen, paracetamol, furosemide, omeprazole).